Tiera A Liby
Overview
Explore the profile of Tiera A Liby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
44
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S, et al.
Sci Rep
. 2025 Feb;
15(1):4294.
PMID: 39905117
Paclitaxel is a standard of care neoadjuvant therapy for patients with triple negative breast cancer (TNBC); however, it shows limited benefit for locally advanced or metastatic disease. Here we used...
2.
Berens E, Khou S, Huang E, Hoffman A, Johnson B, Kirchberger N, et al.
bioRxiv
. 2025 Feb;
PMID: 39896558
Statement Of Significance: Neoplastic breast epithelial cells express surface receptors canonically attributed to leukocytes and are associated with therapy resistance and aggressive tumor behavior.
3.
Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S, et al.
bioRxiv
. 2024 Jun;
PMID: 38895265
Paclitaxel is a standard of care neoadjuvant therapy for patients with triple negative breast cancer (TNBC); however, it shows limited benefit for locally advanced or metastatic disease. Here we used...
4.
Gross S, Mohammadi F, Sanchez-Aguila C, Zhan P, Liby T, Dane M, et al.
Nat Commun
. 2023 Jun;
14(1):3450.
PMID: 37301933
Identifying effective therapeutic treatment strategies is a major challenge to improving outcomes for patients with breast cancer. To gain a comprehensive understanding of how clinically relevant anti-cancer agents modulate cell...
5.
Gross S, Dane M, Smith R, Devlin K, McLean I, Derrick D, et al.
Commun Biol
. 2022 Oct;
5(1):1066.
PMID: 36207580
The phenotype of a cell and its underlying molecular state is strongly influenced by extracellular signals, including growth factors, hormones, and extracellular matrix proteins. While these signals are normally tightly...
6.
Liby T, Spyropoulos P, Lindner H, Eldridge J, Beeson C, Hsu T, et al.
Int J Cancer
. 2011 Feb;
130(3):532-43.
PMID: 21351097
The PI3 kinase/Akt pathway is commonly deregulated in human cancers, functioning in such processes as proliferation, glucose metabolism, survival and motility. We have previously described a novel function for one...